ストックスクリーナーアプリを入手
8.72
4.49%
-0.41
前日終値:
$9.13
開ける：
$9.92
24時間の取引高:
7.42M
Relative Volume:
6.36
時価総額：
$620.78M
収益：
-
当期純損益:
$-34.98M
株価収益率:
-9.4793
EPS:
-0.9199
ネットキャッシュフロー:
$-32.77M
1週間 パフォーマンス:
+7.65%
1か月 パフォーマンス:
-3.00%
6か月 パフォーマンス:
+52.71%
1年 パフォーマンス:
+264.85%
1日の値動き範囲:
$8.63
$10.19
1週間の範囲:
$8.04
$10.19
52週間の値動き範囲:
$1.94
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
名前
Immix Biopharma Inc
セクター
電話
(888) 958-1084
住所
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
8.72 | 620.78M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-25 | 開始されました | Morgan Stanley | Overweight |
| 2026-03-09 | 開始されました | Citizens | Mkt Outperform |
| 2026-02-09 | 開始されました | Mizuho | Outperform |
Immix Biopharma Inc (IMMX) 最新ニュース
Wall Street analysts think Immix Biopharma (IMMX) could surge 113.58%: Read this before placing a bet - MSN
Immix Biopharma analyst bullish but flags safety, adoption questions - MSN
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions - Benzinga
BofA initiates Immix Biopharma stock with buy rating on AL amyloidosis drug - Investing.com UK
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet - Yahoo Finance
Immix Biopharma, Inc. Stock 12‑Month Price Target Raised to $19.79, Implies 117% Upside - TradingView
IMMX Initiates Coverage by B of A Securities -- Rating Set to Bu - GuruFocus
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immix Biopharma Inc (IMMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immix Biopharma Inc (IMMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IMMX Initiates Coverage On LifeSci Capital -- Rating at Outperfo - GuruFocus
Immix Biopharma Inc (IMMX) Institutional Confidence - TradingKey
Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IMMX Q1 2026 Earnings: EPS Beat Reflects Cost Discipline Amid Pre-Revenue Biotech Pipeline ProgressProfit Guidance Range - newsline.com
Immix Biopharma Inc (IMMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMMX Q1 2026 Earnings: Biotech Reports Narrower-than-Expected Loss, Shares GainEPS Estimate Trend - newsline.com
Immix Biopharma Surges 5.3% as Biotech Sentiment Lifts IMMXProfit Surge Picks - newsline.com
Wall Street analysts see a 120.59% upside in Immix Biopharma (IMMX): Can the stock really move this high? - MSN
What's going on with Immix Biopharma stock Thursday? - MSN
Janus Henderson files 13G/A: 9.09M shares of Immix Biopharma (IMMX) - Stock Titan
IMMX News | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
IMMX Technical Analysis | Trend, Signals & Chart Patterns | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
Immix Biopharma, Inc. Files Form 8-K Announcing Election of Directors and Corporate Details (May 2026) - Minichart
Immix Biopharma Shareholders Back Board and Auditor at AGM - TipRanks
Immix Biopharma (NASDAQ: IMMX) posts 2026 annual shareholder voting outcomes - Stock Titan
Immix Biopharma (IMMX) awards RSUs and stock options to director Helen Adams - Stock Titan
Immix Biopharma (IMMX) director Carey Ng awarded RSUs, 12,500-share option - Stock Titan
Immix Biopharma (NASDAQ: IMMX) grants RSUs and stock options to director - Stock Titan
Immix Biopharma (IMMX) CFO, President awarded 500,000 stock options at $8.78 - Stock Titan
Immix Biopharma (IMMX) director receives 6,250 RSUs and 12,500 options - Stock Titan
Immix Biopharma (IMMX) awards CEO 500,000 stock options at $8.78 strike - Stock Titan
Immix Biopharma (IMMX) director awarded RSUs and stock options in new grants - Stock Titan
Immix Biopharma (IMMX) board member receives new RSU and stock option awards - Stock Titan
Immix Biopharma (IMMX) director Jane Buchan awarded RSUs and 12,500 stock options - Stock Titan
Immix Biopharma Q1 2026 Earnings: Narrower-than-Expected Loss Drives Modest Stock UptickQuarterly Profit Report - newsline.com
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? - Yahoo Finance
What date does Immix Biopharma's (IMMX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Immix Biopharma closes $140.65 million offering - The Pharma Letter
Immix Biopharma stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com Nigeria
IMMX Q1 2026 Earnings: Narrowed Loss as Biotech Advances Oncology PipelineEarnings Outlook Update - Newser
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock - The Manila Times
Immix Biopharma closes $140.65 million stock offering By Investing.com - Investing.com Australia
Immix Biopharma Announces Closing of $150 Mil - Moomoo
Immix Biopharma closes $140.65 million stock offering - Investing.com UK
IMMX Maintained by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus
Immix Biopharma Inc (IMMX) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):